An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma

详细信息    查看全文

• 作者：Sabrina Bimonte (1)
  Antonio Barbieri (2)
  Raffaele Palaia (1)
  Maddalena Leongito (1)
  Vittorio Albino (1)
  Mauro Piccirillo (1)
  Claudio Arra (2)
  Francesco Izzo (1)
  
  1. Hepatobiliary Unit ; Istituto Nazionale per lo studio e la cura dei Tumori 鈥淔ondazione G. Pascale鈥? IRCCS- Via Mariano Semmola ; 80131 ; Naples ; Italy
  2. INT Facility ; Istituto Nazionale per lo studio e la cura dei Tumori 鈥淔ondazione G. Pascale鈥? IRCCS- Via Mariano Semmola ; 80131 ; Naples ; Italy
  
• 关键词：Loco ; regional treatments ; Hepatocellular carcinoma ; Drug delivery ; Safety ; Efficacy
• 刊名：Infectious Agents and Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：10
• 期：1
• 全文大小：325 KB
• 参考文献：1. Parkin, DM, Bray, F, Ferlay, J, Pisani, P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: pp. 74-108 3322/canjclin.55.2.74" target="_blank" title="It opens in new window">CrossRef
  2. Izzo, F, Albino, V, Palaia, R, Piccirillo, M, Tatangelo, F, Granata, V (2014) Hepatocellular carcinoma: preclinical data on a dual-lumen catheter kit for fibrin sealant infusion following loco-regional treatments. Infect Agent Cancer 9: pp. 39 378-9-39" target="_blank" title="It opens in new window">CrossRef
  3. Davis, GL, Alter, MJ, El-Serag, H, Poynard, T, Jennings, LW (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: pp. 513-21 3/j.gastro.2009.09.067" target="_blank" title="It opens in new window">CrossRef
  4. Olsen, AH, Parkin, DM, Sasieni, P (2008) Cancer mortality in the United Kingdom: projections to the year 2025. Br J Cancer 99: pp. 1549-54 38/sj.bjc.6604710" target="_blank" title="It opens in new window">CrossRef
  5. Boucher, E, Forner, A, Reig, M, Bruix, J (2009) New drugs for the treatment of hepatocellular carcinoma. Liver Int 29: pp. 148-58 3231.2008.01929.x" target="_blank" title="It opens in new window">CrossRef
  6. Kumagi, T, Hiasa, Y, Hirschfield, GM (2009) Hepatocellular carcinoma for the non-specialist. BMJ 339: pp. b5039 36/bmj.b5039" target="_blank" title="It opens in new window">CrossRef
  7. Lencioni, R (2010) Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 78: pp. 107-12 315238" target="_blank" title="It opens in new window">CrossRef
  8. Lencioni, R (2010) Loco-regional treatment of hepatocellular carcinoma. Hepatology 52: pp. 762-73 3725" target="_blank" title="It opens in new window">CrossRef
  9. Himoto, T, Kurokohchi, K, Watanabe, S, Masaki, T (2012) Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma. Hepat Mon 12: pp. e5945 CrossRef
  10. Bleicher, RJ, Allegra, DP, Nora, DT, Wood, TF, Foshag, LJ, Bilchik, AJ (2003) Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10: pp. 52-8 3.03.018" target="_blank" title="It opens in new window">CrossRef
  11. Breton, M, Haggerty, J, Roberge, D, Freeman, GK (2012) Management continuity in local health networks. Int J Integr Care 12: pp. e14
  12. Khan, KN, Yatsuhashi, H, Yamasaki, K, Yamasaki, M, Inoue, O, Koga, M (2000) Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 32: pp. 269-78 CrossRef
  13. Koda, M, Tanaka, H, Murawaki, Y, Horie, Y, Suou, T, Kawasaki, H (2000) Liver perforation: a serious complication of percutaneous acetic acid injection for hepatocellular carcinoma. Hepatogastroenterology 47: pp. 1110-2
  14. Huo, TI, Lee, SD, Wu, JC (2003) Screening for hepatocellular carcinoma in high-risk patients: Western versus Eastern virus. Hepatology 38: pp. 269 3/jhep.2003.50236" target="_blank" title="It opens in new window">CrossRef
  15. Lencioni, RA, Allgaier, HP, Cioni, D, Olschewski, M, Deibert, P, Crocetti, L (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228: pp. 235-40 CrossRef
  16. Lin, SM, Lin, CJ, Lin, CC, Hsu, CW, Chen, YC (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma鈥?鈥塷r =4聽cm. Gastroenterology 127: pp. 1714-23 3/j.gastro.2004.09.003" target="_blank" title="It opens in new window">CrossRef
  17. Shiina, S, Teratani, T, Obi, S, Sato, S, Tateishi, R, Fujishima, T (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: pp. 122-30 3/j.gastro.2005.04.009" target="_blank" title="It opens in new window">CrossRef
  18. Lin, SM, Lin, CJ, Lin, CC, Hsu, CW, Chen, YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3聽cm or less. Gut 54: pp. 1151-6 36/gut.2004.045203" target="_blank" title="It opens in new window">CrossRef
  19. Cho, YK, Kim, JK, Kim, MY, Rhim, H, Han, JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: pp. 453-9 CrossRef
  20. Curley, SA, Izzo, F, Delrio, P, Ellis, LM, Granchi, J, Vallone, P (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230: pp. 1-8 CrossRef
  21. Pearson, AS, Izzo, F, Fleming, RY, Ellis, LM, Delrio, P, Roh, MS (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178: pp. 592-9 34-2" target="_blank" title="It opens in new window">CrossRef
  22. Izzo, F, Barnett, CC, Curley, SA (2001) Radiofrequency ablation of primary and metastatic malignant liver tumors. Adv Surg 35: pp. 225-50
  23. Komorizono, Y, Oketani, M, Sako, K, Yamasaki, N, Shibatou, T, Maeda, M (2003) Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 97: pp. 1253-62 CrossRef
  24. Llovet, JM, Vilana, R, Bianchi, L, Bru, C (2001) [Radiofrequency in the treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 24: pp. 303-11 CrossRef
  25. Llovet, JM, Vilana, R, Bru, C, Bianchi, L, Salmeron, JM, Boix, L (2001) Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33: pp. 1124-9 3/jhep.2001.24233" target="_blank" title="It opens in new window">CrossRef
  26. Teratani, T, Yoshida, H, Shiina, S, Obi, S, Sato, S, Tateishi, R (2006) Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 43: pp. 1101-8 CrossRef
  27. Yu, NC, Lu, DS, Raman, SS, Dupuy, DE, Simon, CJ, Lassman, C (2006) Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters鈥損ilot comparison with pathologic findings. Radiology 239: pp. 269-75 383041592" target="_blank" title="It opens in new window">CrossRef
  28. Pacella, CM, Francica, G, Lascio, FM, Arienti, V, Antico, E, Caspani, B (2009) Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol 27: pp. 2615-21 CrossRef
  29. Shimizu, T, Sakuhara, Y, Abo, D, Hasegawa, Y, Kodama, Y, Endo, H (2009) Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 16: pp. 816-23 34-009-0124-4" target="_blank" title="It opens in new window">CrossRef
  30. Lencioni, R, Crocetti, L, Simone, P, Filipponi, F (2010) Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int 23: pp. 698-703 32-2277.2010.01109.x" target="_blank" title="It opens in new window">CrossRef
  31. Guo, Y, Zhang, Y, Nijm, GM, Sahakian, AV, Yang, GY, Omary, RA (2011) Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones. Radiology 258: pp. 461-8 CrossRef
  32. Bruix, J, Llovet, JM (2001) Hepatocellular carcinoma: is surveillance cost effective?. Gut 48: pp. 149-50 36/gut.48.2.149" target="_blank" title="It opens in new window">CrossRef
  33. Varela, M, Real, MI, Burrel, M, Forner, A, Sala, M, Brunet, M (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46: pp. 474-81 CrossRef
  34. Lammer, J, Malagari, K, Vogl, T, Pilleul, F, Denys, A, Watkinson, A (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33: pp. 41-52 CrossRef
  35. Malagari, K, Pomoni, M, Kelekis, A, Pomoni, A, Dourakis, S, Spyridopoulos, T (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33: pp. 541-51 CrossRef
  36. Nicolini, A, Martinetti, L, Crespi, S, Maggioni, M, Sangiovanni, A (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21: pp. 327-32 38" target="_blank" title="It opens in new window">CrossRef
  37. Geschwind, JF, Salem, R, Carr, BI, Soulen, MC, Thurston, KG, Goin, KA (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127: pp. S194-205 3/j.gastro.2004.09.034" target="_blank" title="It opens in new window">CrossRef
  38. Ibrahim, SM, Lewandowski, RJ, Ryu, RK, Sato, KT, Gates, VL, Mulcahy, MF (2008) Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments. Cardiovasc Intervent Radiol 31: pp. 1124-32 348-y" target="_blank" title="It opens in new window">CrossRef
  39. Salem, R, Hunter, RD (2006) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys 66: pp. S83-8 CrossRef
  40. Sangro, B, Bilbao, JI, Boan, J, Martinez-Cuesta, A, Benito, A, Rodriguez, J (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66: pp. 792-800 CrossRef
  41. Kulik, LM, Atassi, B, Holsbeeck, L, Souman, T, Lewandowski, RJ, Mulcahy, MF (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94: pp. 572-86 CrossRef
  42. Llovet, JM, Ricci, S, Mazzaferro, V, Hilgard, P, Gane, E, Blanc, JF (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: pp. 378-90 CrossRef
  43. Cheng, AL, Kang, YK, Chen, Z, Tsao, CJ, Qin, S, Kim, JS (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: pp. 25-34 CrossRef
  44. Wang, B, Xu, H, Gao, ZQ, Ning, HF, Sun, YQ, Cao, GW (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49: pp. 523-9 CrossRef
  45. Virmani, S, Rhee, TK, Ryu, RK, Sato, KT, Lewandowski, RJ, Mulcahy, MF (2008) Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 19: pp. 1483-9 CrossRef
  46. Lencioni, R, Llovet, JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: pp. 52-60 30-1247132" target="_blank" title="It opens in new window">CrossRef
  47. Raut, CP, Izzo, F, Marra, P, Ellis, LM, Vauthey, JN, Cremona, F (2005) Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol 12: pp. 616-28 CrossRef
  48. Curley, SA, Izzo, F (2002) Radiofrequency ablation of hepatocellular carcinoma. Minerva Chir 57: pp. 165-76
  49. Curley, SA, Izzo, F (2002) Radiofrequency ablation of primary and metastatic hepatic malignancies. Int J Clin Oncol 7: pp. 72-81
  50. Curley, SA, Cusack, JC, Tanabe, KK, Stoelzing, O, Ellis, LM (2002) Advances in the treatment of liver tumors. Curr Probl Surg 39: pp. 449-571 CrossRef
  51. Golfieri, R, Bilbao, JI, Carpanese, L, Cianni, R, Gasparini, D, Ezziddin, S (2013) Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol 59: pp. 753-61 3.05.025" target="_blank" title="It opens in new window">CrossRef
  52. Li, G, Dong, S, Qu, J, Sun, Z, Huang, Z, Ye, L (2010) Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver Int 30: pp. 585-92 3231.2009.02113.x" target="_blank" title="It opens in new window">CrossRef
  53. Nobuoka, D, Motomura, Y, Shirakawa, H, Yoshikawa, T, Kuronuma, T, Takahashi, M (2012) Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol 40: pp. 63-70
  54. Beebe, SJ, Fox, PM, Rec, LJ, Willis, EL, Schoenbach, KH (2003) Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells. FASEB J 17: pp. 1493-5
  55. Yin, S, Chen, X, Hu, C, Zhang, X, Hu, Z, Yu, J (2014) Nanosecond pulsed electric field (nsPEF) treatment for hepatocellular carcinoma: a novel locoregional ablation decreasing lung metastasis. Cancer Lett 346: pp. 285-91 CrossRef
  56. Raoof, M, Corr, SJ, Zhu, C, Cisneros, BT, Kaluarachchi, WD, Phounsavath, S (2014) Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomedicine 10: pp. 1121-30 3.004" target="_blank" title="It opens in new window">CrossRef
  
• 刊物主题：Cancer Research; Infectious Diseases; Oncology;
• 出版者：BioMed Central
• ISSN：1750-9378

文摘

Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer mouse models have been performed. This review will focus on the latest papers on the efficacy of loco-regional therapy and combined treatments in patients and mouse models of hepatocellular carcinoma.